Limited agents that act on fatty acid synthesis are in clinical development, but the fatty acid synthase inhibitor, epigallo-catechin gallate has been evaluated in phase 1 and 2 trials.
ACC: Acetyl-CoA carboxylase; ACL: Adenosine triphosphate citrate lyase; CoA: Coenzyme A; EGCG: Epigallocatechin gallate; FAS: Fatty acid synthase; NAD: Nicotinamide adenine dinucleotide; OAA: Oxaloacetic acid; TCA: Tricarboxylic acid cycle.